Report Detail
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Growth (Status and Outlook) 2022-2028
- RnM4498115 |
- 13 December, 2022 |
- Global |
- 110 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
The global market for Treatment of Chemotherapy-Induced Nausea in Cancer Patients is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Treatment of Chemotherapy-Induced Nausea in Cancer Patients players cover Heron Therapeutics, Merck, Eisai, Mundipharma and Qilu Pharma, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market, with both quantitative and qualitative data, to help readers understand how the Treatment of Chemotherapy-Induced Nausea in Cancer Patients market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Treatment of Chemotherapy-Induced Nausea in Cancer Patients market and forecasts the market size by Type (5-HT3 Inhibitors, NK1 Inhibitors and Other), by Application (Acute CINV, Delayed CINV, Breakthrough CINV and Others), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segmentation by application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Chapter Introduction
Chapter 1: Scope of Treatment of Chemotherapy-Induced Nausea in Cancer Patients, Research Methodology, etc.
Chapter 2: Executive Summary, global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size and CAGR, Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Treatment of Chemotherapy-Induced Nausea in Cancer Patients revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche and Mylan, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2017-2028
- 2.1.2 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size CAGR by Region 2017 VS 2022 VS 2028
- 2.2 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Segment by Type
- 2.2.1 5-HT3 Inhibitors
- 2.2.2 NK1 Inhibitors
- 2.2.3 Other
- 2.3 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type
- 2.3.1 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size CAGR by Type (2017 VS 2022 VS 2028)
- 2.3.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Type (2017-2022)
- 2.4 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Segment by Application
- 2.4.1 Acute CINV
- 2.4.2 Delayed CINV
- 2.4.3 Breakthrough CINV
- 2.4.4 Others
- 2.5 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application
- 2.5.1 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size CAGR by Application (2017 VS 2022 VS 2028)
- 2.5.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application (2017-2022)
3 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Player
- 3.1 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Players
- 3.1.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue by Players (2020-2022)
- 3.1.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue Market Share by Players (2020-2022)
- 3.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Treatment of Chemotherapy-Induced Nausea in Cancer Patients by Regions
- 4.1 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Regions (2017-2022)
- 4.2 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth (2017-2022)
- 4.3 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth (2017-2022)
- 4.4 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth (2017-2022)
- 4.5 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth (2017-2022)
5 Americas
- 5.1 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2017-2022)
- 5.2 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022)
- 5.3 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Region (2017-2022)
- 6.2 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022)
- 6.3 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
7 Europe
- 7.1 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients by Country (2017-2022)
- 7.2 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022)
- 7.3 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients by Region (2017-2022)
- 8.2 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022)
- 8.3 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Regions (2023-2028)
- 10.1.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Regions (2023-2028)
- 10.1.2 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast
- 10.1.3 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast
- 10.1.4 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast
- 10.1.5 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast
- 10.2 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Country (2023-2028)
- 10.2.1 United States Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.2.2 Canada Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.2.3 Mexico Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.2.4 Brazil Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.3 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Region (2023-2028)
- 10.3.1 China Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.3.2 Japan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.3.3 Korea Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.3.4 Southeast Asia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.3.5 India Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.3.6 Australia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.4 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Country (2023-2028)
- 10.4.1 Germany Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.4.2 France Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.4.3 UK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.4.4 Italy Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.4.5 Russia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.5 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Region (2023-2028)
- 10.5.1 Egypt Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.5.2 South Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.5.3 Israel Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.5.4 Turkey Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.5.5 GCC Countries Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
- 10.6 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Type (2023-2028)
- 10.7 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Application (2023-2028)
11 Key Players Analysis
- 11.1 Heron Therapeutics
- 11.1.1 Heron Therapeutics Company Information
- 11.1.2 Heron Therapeutics Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.1.3 Heron Therapeutics Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.1.4 Heron Therapeutics Main Business Overview
- 11.1.5 Heron Therapeutics Latest Developments
- 11.2 Merck
- 11.2.1 Merck Company Information
- 11.2.2 Merck Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.2.3 Merck Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.2.4 Merck Main Business Overview
- 11.2.5 Merck Latest Developments
- 11.3 Eisai
- 11.3.1 Eisai Company Information
- 11.3.2 Eisai Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.3.3 Eisai Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.3.4 Eisai Main Business Overview
- 11.3.5 Eisai Latest Developments
- 11.4 Mundipharma
- 11.4.1 Mundipharma Company Information
- 11.4.2 Mundipharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.4.3 Mundipharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.4.4 Mundipharma Main Business Overview
- 11.4.5 Mundipharma Latest Developments
- 11.5 Qilu Pharma
- 11.5.1 Qilu Pharma Company Information
- 11.5.2 Qilu Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.5.3 Qilu Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.5.4 Qilu Pharma Main Business Overview
- 11.5.5 Qilu Pharma Latest Developments
- 11.6 Teva
- 11.6.1 Teva Company Information
- 11.6.2 Teva Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.6.3 Teva Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.6.4 Teva Main Business Overview
- 11.6.5 Teva Latest Developments
- 11.7 Novartis
- 11.7.1 Novartis Company Information
- 11.7.2 Novartis Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.7.3 Novartis Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.7.4 Novartis Main Business Overview
- 11.7.5 Novartis Latest Developments
- 11.8 Roche
- 11.8.1 Roche Company Information
- 11.8.2 Roche Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.8.3 Roche Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.8.4 Roche Main Business Overview
- 11.8.5 Roche Latest Developments
- 11.9 Mylan
- 11.9.1 Mylan Company Information
- 11.9.2 Mylan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.9.3 Mylan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.9.4 Mylan Main Business Overview
- 11.9.5 Mylan Latest Developments
- 11.10 Baxter
- 11.10.1 Baxter Company Information
- 11.10.2 Baxter Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.10.3 Baxter Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.10.4 Baxter Main Business Overview
- 11.10.5 Baxter Latest Developments
- 11.11 GSK
- 11.11.1 GSK Company Information
- 11.11.2 GSK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.11.3 GSK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.11.4 GSK Main Business Overview
- 11.11.5 GSK Latest Developments
- 11.12 Helsinn
- 11.12.1 Helsinn Company Information
- 11.12.2 Helsinn Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.12.3 Helsinn Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.12.4 Helsinn Main Business Overview
- 11.12.5 Helsinn Latest Developments
- 11.13 Southwest Pharma
- 11.13.1 Southwest Pharma Company Information
- 11.13.2 Southwest Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.13.3 Southwest Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.13.4 Southwest Pharma Main Business Overview
- 11.13.5 Southwest Pharma Latest Developments
- 11.14 Haisco
- 11.14.1 Haisco Company Information
- 11.14.2 Haisco Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.14.3 Haisco Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.14.4 Haisco Main Business Overview
- 11.14.5 Haisco Latest Developments
- 11.15 Sun Pharma
- 11.15.1 Sun Pharma Company Information
- 11.15.2 Sun Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
- 11.15.3 Sun Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
- 11.15.4 Sun Pharma Main Business Overview
- 11.15.5 Sun Pharma Latest Developments
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Treatment of Chemotherapy-Induced Nausea in Cancer Patients. Industry analysis & Market Report on Treatment of Chemotherapy-Induced Nausea in Cancer Patients is a syndicated market report, published as Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Treatment of Chemotherapy-Induced Nausea in Cancer Patients market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
